Figure S5. Adding anti-PD-1 treatment to the DNMTi/HDAC6i combination does not increase the epigenetic treatment's effect on tumor burden or survival. A) C57Bl6 mice were injected with ID8 Trp53-/-cells and treated with 0.5 mg/mL Aza daily every other week and 25 mg/kg NextA daily every other week (alternating, see schematic in Figure S5C). Mice were given 200 µg anti-PD-1 or isotype control twice a week. The NextA + Aza and the NextA + Aza + anti-PD-1 groups had significantly longer survival (days indicated next to the legend) compared to the Mock group. * p < 0.05 by log-rank (Mantel-Cox) test. B) Ascites volume (tumor burden) was measured at Week 8. C) Schematic.
. The HDAC6 inhibitor Nexturastat A causes cell death in ovarian cancer cell lines with and without the DNMTi 5-azacytidine. Ovarian cancer cell lines were treated with indicated concentrations of the HDAC6 inhibitor Nexturastat A (NextA) and 500 nM of the DNMT inhibitor 5-azacytidine (Aza) in the following treatment schema: 3 days of Aza treatment followed by 2 days of NextA treatment. Cytotoxicity was assessed at Days 4 (A) and 7 (B).
Cytotoxicity assays were performed on all cell lines to find an appropriate treatment concentration and to measure the effect of the combination treatment at different time points.
Figure S2. The HDAC6 inhibitor Nexturastat A inhibits HDAC6 in ovarian cancer cell lines.
Ovarian cancer cell lines were treated with indicated concentrations of NextA and broader spectrum HDAC inhibitors Givinostat (Class I & Class II HDACi), LBH (pan-HDACi), TSA (pan-HDACi). The percent inhibition of HDAC activity was calculated using the HDAC-Glo assay in the following cell lines: A) A2780, B) Hey, C) Kuramochi, D) SKOV3 E) TYKnu, F) ID8 Trp53-/-.
The optimal NextA dose for each cell line was chosen as the dose that inhibited greater than 50% of HDAC activity while not causing more than 20% cytotoxicity. after treatment with IFN-gamma (IFN-g +) or control (IFN-g -) . Protein was isolated and immunoblots were run for PD-L1, acetylated tubulin, and a-tubulin as a loading control. Cropped blots are shown here and black lines indicate where one part of the blot ends and another begins. Figure S7F shows the entire blot images. B) Hey human ovarian cancer cells were treated as in Figure 1 and cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for PD-L1 surface marker by flow cytometry. A one way ANOVA was performed for statistical significance: * p < 0.05 compared to Mock; # p < 0.05 compared to NextA; + p < 0.05 compared to Aza. C) ID8 Trp53-/-ovarian cancer cells were treated as in Figure 1 and cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for PD-L1 surface marker by flow cytometry. A one way ANOVA was performed for statistical significance: * p < 0.05 compared to Mock; # p < 0.05 compared to NextA; + p < 0.05 compared to Aza. D) SKOV3 CR human ovarian cancer cells were treated as in Figure 1 and cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for PD-L1 surface marker by flow cytometry. E) IGROV-1 CR human ovarian cancer cells were treated as in Figure 1 and cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for PD-L1 surface marker by flow cytometry.
Figure S4. Epigenetic therapies increase immune signaling in cisplatin-resistant cell lines. A)
Protein was isolated from the IGROV-1 CR and SKOV3 CR human ovarian cancer cell lines and levels of HDACs 1, 2, and 6 were assessed. a-tubulin was used as a loading control.
HDAC1 and HDAC6 were run on the same blot which was cut to image, then stripped and reprobed for HDAC2 and stripped and reprobed for a-tubulin. Cropped blots are shown here and black lines indicate where one part of the blot ends and another begins. Figure S7G shows the entire blot images. RNA was isolated from the SKOV3 CR (B) and IGROV-1 CR (C) cell lines at Day 7 of the treatment schema in Figure 1 and qRT-PCR was performed for ISGs IFI27, OASL, IFI44L, and IFNB1 and cytokines CCL2, CCL5, and CXCL10. Fold change is indicated relative to Mock for each of the following treatments: NextA (blue), Aza (red), and NextA + Aza The SKOV3 CR cell line were treated as in Figure 1 and protein was extracted at Day 7 after treatment with IFN-gamma (IFN-g +) (to assess MHC I and PD-L1 expression) or control (IFN-g -). D) Protein was isolated and immunoblots were run for DNMT1, PD-L1, Acetyl-tubulin (AC tubulin), and a-tubulin as a loading control. Cropped blots are shown here, and black lines indicate where one part of the blot ends and another begins. Figure S7H shows the entire blot images. E) Cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for MHC I surface marker by flow cytometry. The IGROV-1 CR cell line were treated as in Figure 1 and protein was extracted at Day 7 after treatment with IFNgamma (IFN-g +) (to assess MHC I and PD-L1 expression) or control (IFN-g -). F) Protein was isolated and immunoblots were run for DNMT1, PD-L1, Acetyl-tubulin (AC tubulin), and atubulin as a loading control. Cropped blots are shown here, and black lines indicate where one part of the blot ends and another begins. Figure S7H shows the entire blot images. G) Cells were prepared at Day 7 after treatment with IFN-gamma (IFN-g +) or control (IFN-g -). Cells were stained for MHC I surface marker by flow cytometry.
Figure S6. Adding anti-PD-1 treatment to the DNMTi/HDAC6i combination does not increase the Combo treatments effect on the immune microenvironment. C57Bl6 mice
were injected with ID8 Trp53-/-cells and treated with 0.5 mg/mL Aza daily every other week and 25 mg/kg NextA daily every other week (alternating, see schematic in Figure S5C ). Mice were given 200 µg anti-PD-1 or isotype control twice a week. Ascites were drained from the mice and immunophenotyping was performed on all mice as in Figures 6-8.
Figure S7. Full blot images from all immunoblots.
A) Full blot images from Figure 1A . Protein was isolated from six different human ovarian cancer cell lines and levels of HDACs 1, 2, and 6 were assessed. a-tubulin was used as a loading control. HDAC1 and HDAC6 were run on the same blot which was cut to image, then stripped and reprobed for HDAC2 and stripped and reprobed for a-tubulin as shown in Figure   1A . Figure 3A . Ovarian cancer cell lines were treated as in Figure 1 and protein was extracted at Day 7 after treatment with IFN-gamma (IFN-g +) (to assess MHC I and PD-L1 expression, in later figures) or control (IFN-g -). Protein was isolated and immunoblots were run for the DNMT1 protein and a-tubulin as a loading control. Immunoblot membranes were cut and probed separately for DNMT1 (about 188 kDa) and a-tubulin (50 kDa). Figure 3B . The TykNu cell line was treated as in A) and the protein synthesis cycloheximide added to cells on Day 7 for 0, 4, and 8 hours at 10 µM as indicated on the blot. Protein was isolated and immunoblots were run for the DNMT1 protein and a-tubulin as a loading control. Immunoblot membranes were cut and probed separately for DNMT1 (about 188 kDa) and a-tubulin (50 kDa). Cropped blots are shown in Figure 3B 
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